gefitinib has been researched along with 2-acetylfuranonaphthoquinone in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (2-acetylfuranonaphthoquinone) | Trials (2-acetylfuranonaphthoquinone) | Recent Studies (post-2010) (2-acetylfuranonaphthoquinone) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 79 | 11 | 65 |
| Protein | Taxonomy | gefitinib (IC50) | 2-acetylfuranonaphthoquinone (IC50) |
|---|---|---|---|
| Retinal dehydrogenase 1 | Homo sapiens (human) | 0.4253 | |
| Signal transducer and activator of transcription 3 | Homo sapiens (human) | 2.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, J; Lu, B; Lv, H; Sun, Y; Wang, Q; Yu, J; Zhang, Y; Zhou, Q | 1 |
1 other study(ies) available for gefitinib and 2-acetylfuranonaphthoquinone
| Article | Year |
|---|---|
STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Mutation; Naphthoquinones; Neoplasm Invasiveness; Protein Kinase Inhibitors; Receptor Tyrosine Kinase-like Orphan Receptors; Signal Transduction; STAT3 Transcription Factor; Tumor Suppressor Protein p53 | 2021 |